UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Biomaterials, 2012-10, Vol.33 (29), p.7164-7173

2012

Volltextzugriff (PDF)

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-05, Vol.27 (5), p.802-805

2021

Volltextzugriff (PDF)

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer

PloS one, 2012-09, Vol.7 (9), p.e44299-e44299

2012

Volltextzugriff (PDF)

A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events

Journal of cell science, 2011-05, Vol.124 (Pt 9), p.1453-1464

2011

Volltextzugriff (PDF)

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046

2021

Volltextzugriff (PDF)

Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-10, Vol.27 (10), p.1849-1849

2021

Volltextzugriff (PDF)

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

Nanomedicine (London, England), 2016-03, Vol.11 (5), p.479-494

2016

Volltextzugriff (PDF)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer

PloS one, 2012-09, Vol.7 (9)

2012

Volltextzugriff (PDF)

Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles

Nanomedicine (London, England), 2015-03, Vol.10 (6), p.915-929

2015

Volltextzugriff (PDF)

Radiosynthesis of clinical doses of 68 Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68 Ge/ 68 Ga generators

Nuclear medicine and biology, 2016-01, Vol.43 (1), p.19-26

2016

Volltextzugriff (PDF)

A comparative study of phytoestrogen action in mitigating apoptosis induced by oxidative stress

In vivo (Athens), 2012-09, Vol.26 (5), p.765-775

2012

Volltextzugriff (PDF)

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

The New England journal of medicine, 2021-11, Vol.385 (22), p.2036-2046

2021

Volltextzugriff (PDF)

sup 64^Cu-labeled dimeric glucosamine conjugates and their evaluation in metastatic melanoma cancer cells

The Journal of nuclear medicine (1978), 2017-05, Vol.58, p.676

2017

Volltextzugriff (PDF)

An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS680-TPS680

2019

Volltextzugriff (PDF)

Inhibition of hypoxia-inducible factor-2[alpha] in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-05, Vol.27 (5), p.802

2021

Volltextzugriff (PDF)

The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.273-273

2021

Volltextzugriff (PDF)

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.333-333

2021

Volltextzugriff (PDF)

Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.558-558

2019

Volltextzugriff (PDF)

Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5003-5003

2020

Volltextzugriff (PDF)

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.611-611

2020

Volltextzugriff (PDF)

Treatment of high grade metastatic neuroendocrine tumor (mNET) with peptide receptor radionuclide therapy (PRRT): Retrospective analysis in a single referral center

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15175-e15175

2015

Volltextzugriff (PDF)

Abstract 1270: Mimicking infection for immunotherapy against breast cancer - fooling the immune system

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1270-1270

2013

Volltextzugriff (PDF)

A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging

Nanotechnology, 2011-07, Vol.22 (29), p.295104-295104

2011

Volltextzugriff (PDF)

Radiosynthesis of clinical doses of 68Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68Ge/68Ga generators

Nuclear medicine and biology, 2016-01, Vol.43 (1), p.19-26

2016

Volltextzugriff (PDF)

Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2013-05, Vol.15 (5), p.1, Article 1646

2013

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)
Dissertationen
(2)

Sprache

Englisch
(35)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Humans
(8)
Life Sciences & Biomedicine
(7)
Female
(6)
Animals
(5)
Breast Cancer
(5)
Nanoparticles - Chemistry
(5)
Science & Technology - Other Topics
(5)
Mice
(4)
Nanoparticles
(4)
Nanoscience & Nanotechnology
(4)
Antineoplastic Agents - Therapeutic Use
(3)
Cancer
(3)
Cell Line, Tumor
(3)
Health Aspects
(3)
Lactic Acid - Chemistry
(3)
Ligands
(3)
Materials Science
(3)
Nanoparticle
(3)
Particle Size
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer

A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer

Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles

Radiosynthesis of clinical doses of 68 Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68 Ge/ 68 Ga generators

A comparative study of phytoestrogen action in mitigating apoptosis induced by oxidative stress

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

sup 64^Cu-labeled dimeric glucosamine conjugates and their evaluation in metastatic melanoma cancer cells

An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma

Inhibition of hypoxia-inducible factor-2[alpha] in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)

Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC

Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

Treatment of high grade metastatic neuroendocrine tumor (mNET) with peptide receptor radionuclide therapy (PRRT): Retrospective analysis in a single referral center

Abstract 1270: Mimicking infection for immunotherapy against breast cancer - fooling the immune system

A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging

Radiosynthesis of clinical doses of 68Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68Ge/68Ga generators

Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Suchergebnisse filtern